|
|
Article: Research in the area of asthma reported from C. Laforce and colleagues.(Clinical report)
- Article from:
- Biotech Week
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
In this recent study, researchers in the United States conducted a study "To assess the 24-h bronchodilator efficacy and safety of single-dose indacaterol in asthma. This was a five-period, double-blind, double- dummy, crossover study in patients with persistent asthma."
"On separate study days, patients inhaled a single dose of indacaterol (150, 300 or 600 mg) in the morning via a single-dose dry powder inhaler (SDDPI), formoterol 12 mg twice daily via its proprietary SDDPI, or placebo. days were separated by a washout period of at least 6 days. Of the 45 patients randomized to treatment, 42 completed the study. The 24-h trough FEV1 (primary endpoint) was ...